Navigation Links
Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals
Date:12/22/2009

rop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='79877557';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.celltherapeutics.com/investors_alert">http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL as determined by the FDA (including ODAC), CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


    Media Contact:                       Investors Contact:

    Dan Eramian                          Ed Bell
    T: 206.272.4343                      T: 206.272.4345
    C: 206.854.1200                      Lindsey Jesch Logan
    F: 206.272.4434                      T: 206.272.4347
    E: 
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
2. Dennis Winger Joins Nektar Therapeutics Board of Directors
3. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
4. Oxford BioTherapeutics Appoints Michael Moore as Chairman
5. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
6. Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference
7. Pearl Therapeutics Appoints Howie Rosen to Board of Directors
8. Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
9. Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
10. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
11. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... , July 29, 2015 US-Australian drug ... ) today confirmed it is committed to progressing its ... soon as practicable and to ensure the Company delivers ... Executive Officer, Iain Ross , said the Company ... the lead pre-clinical programs, discovery programs and academic partnerships ...
(Date:7/29/2015)... July 29, 2015  AsureQuality and Ubiquitome have ... for applications in food and primary production sectors. ... real-time PCR device, the Freedom4. AsureQuality ... to the supermarket shelf for producers, processors and ... in animal disease control and pest management and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... appeals to the Senate Judiciary Committee for a hearing regarding covert surveillance ... it were not for the fact that real people are being victimized ... ... Ohio (PRWEB) June 24, 2008 -- As the issue of torturing foreign ...
... -. deCODE genetics,(Nasdaq: DCGN ) today announced that ... R&D event to be held in New York., ... beginning at,1pm Eastern Time/5pm GMT/6pm British Summer time, at ... to last approximately three and a half,hours. The webcast ...
... June 24 ,WuXi PharmaTech (NYSE: WX ) ... announced,that the two companies have entered into a ... which will provide world-class preclinical,contract research services in ... located in a 323,450 square-foot, purpose-built facility in,Suzhou, ...
Cached Biology Technology:Covert Torture, Surveillance Jeopardizes the Freedom of American Citizens 2Covert Torture, Surveillance Jeopardizes the Freedom of American Citizens 3Covert Torture, Surveillance Jeopardizes the Freedom of American Citizens 4deCODE genetics to Webcast Presentations at Annual R&D Event 2deCODE genetics to Webcast Presentations at Annual R&D Event 3Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 2Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 3Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 4
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... measly angstrom's difference in diameter is a road-closed sign: ... water-molecule-sized sports car, say scientists at the University of ... a class of proteins that form trans-membrane channels in ... for water movement between the cell and its environment. ...
... management is the key to regulating cell volume says Dutch ... water by the plasma membrane of animal and human cells. ... balance between water uptake and secretion by the cell plasma ... salt concentrations in and around the cell. Exactly how this ...
... Johns Hopkins who has spent nearly three decades studying ... fever warns that the first widespread outbreak of the ... sign of how humans can inadvertently help spread infectious ... to be published in The New England Journal of ...
Cached Biology News:Cells direct membrane traffic by channel width 2Water management in cells 2Infectious disease expert warns of spread of Rocky Mountain spotted fever 2Infectious disease expert warns of spread of Rocky Mountain spotted fever 3
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
Mouse monoclonal antibody raised against a partial recombinant PRKG1. NCBI Entrez Gene ID = PRKG1...
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Biology Products: